Marshall Wace LLP Buys Shares of 88,987 Bicycle Therapeutics plc (NASDAQ:BCYC)

Marshall Wace LLP purchased a new position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 88,987 shares of the company’s stock, valued at approximately $1,801,000. Marshall Wace LLP owned 0.21% of Bicycle Therapeutics as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in BCYC. Baker BROS. Advisors LP lifted its holdings in Bicycle Therapeutics by 176.1% during the first quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company’s stock valued at $123,076,000 after purchasing an additional 3,152,433 shares during the last quarter. Westfield Capital Management Co. LP lifted its stake in shares of Bicycle Therapeutics by 13.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock valued at $25,869,000 after buying an additional 121,613 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Bicycle Therapeutics by 0.6% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock worth $17,975,000 after buying an additional 4,976 shares during the period. Avoro Capital Advisors LLC bought a new position in Bicycle Therapeutics in the 2nd quarter worth approximately $14,168,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Bicycle Therapeutics by 45.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock valued at $10,001,000 after buying an additional 124,809 shares in the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Insider Buying and Selling at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,212 shares of the company’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the transaction, the chief executive officer now directly owns 380,864 shares in the company, valued at approximately $8,478,032.64. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 4,584 shares of company stock worth $102,040 over the last 90 days. Corporate insiders own 8.50% of the company’s stock.

Analyst Ratings Changes

BCYC has been the subject of a number of analyst reports. Royal Bank of Canada began coverage on Bicycle Therapeutics in a report on Friday, September 6th. They issued an “outperform” rating and a $35.00 price target for the company. Oppenheimer restated an “outperform” rating and issued a $48.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, August 7th. B. Riley cut Bicycle Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $33.00 to $28.00 in a research report on Wednesday, August 7th. JMP Securities reissued a “market outperform” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, September 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of Bicycle Therapeutics in a research note on Monday, September 16th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.56.

Bicycle Therapeutics Trading Up 6.3 %

Shares of BCYC opened at $23.60 on Friday. Bicycle Therapeutics plc has a 1-year low of $12.54 and a 1-year high of $28.20. The company has a market capitalization of $1.01 billion, a P/E ratio of -5.30 and a beta of 0.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.77 and a quick ratio of 14.77. The firm’s 50 day simple moving average is $23.36 and its 200 day simple moving average is $22.92.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.33. Bicycle Therapeutics had a negative net margin of 417.88% and a negative return on equity of 32.80%. The firm had revenue of $9.36 million for the quarter, compared to analysts’ expectations of $6.13 million. The company’s revenue for the quarter was down 17.9% on a year-over-year basis. Sell-side analysts forecast that Bicycle Therapeutics plc will post -3.17 earnings per share for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.